DS-9606 was supposed to be the first antibody-drug conjugate in Daiichi Sankyo’s line of anti-cancer assets to use a modified ...

Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...

Cancer Breakthroughs Threatened by D.C.'s Price Controls ...

Shares of Prelude Therapeutics rose after the company said it has received Food and Drug Administration approval to proceed with a Phase 1 study for blood-cancer treatment. Shares were up 9.4% at ...

BOSTON, MA, UNITED STATES, January 15, 2026 /EINPresswire.com/ -- Oncoheroes Biosciences, a biotech company exclusively ...

A growing body of research has examined the IRA’s implications for pharmaceutical innovation. Much of this literature has focused on the potential impact on the number of new drug launches, 5, 6 but ...

Researchers at City St. George’s, University of London, have identified a new molecular signature that may explain why ...

The field of cancer research has increasingly focused on the metabolic underpinnings of tumorigenesis, recognizing how the reprogramming of cellular energy ...

CAMBRIDGE, England--(BUSINESS WIRE)--Crescendo Biologics Ltd (Crescendo), the developer of novel, targeted, T cell enhancing therapeutics, and Cancer Research UK, the world’s largest independent ...

ImmunityBio Chairman Patrick Soon-Shiong mischaracterized talks with the FDA over the company's cancer drug, sources say.

Advances in cancer research have led to an increasing number and variety of cancer therapies in the development pipeline, but there are concerns that traditional processes for drug development, ...